<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04815187</url>
  </required_header>
  <id_info>
    <org_study_id>20203338</org_study_id>
    <nct_id>NCT04815187</nct_id>
  </id_info>
  <brief_title>Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease</brief_title>
  <official_title>Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>House Ear Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cures Within Reach</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>House Ear Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate a previously FDA-approved medication that is known&#xD;
      to help with allergy symptoms to see if it can decrease symptoms in patients with Meniere's&#xD;
      Disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients with AAO-HNS Vertigo Control Class A or B</measure>
    <time_frame>1 month after treatment initiation</time_frame>
    <description>Percentage of patients in each group with an AAO-HNS Vertigo Control Class A or B result (from daily diary count of number of attacks)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Patients with AAO-HNS Vertigo Control Class A or B</measure>
    <time_frame>3 months after treatment initiation</time_frame>
    <description>Percentage of patients in each group with an AAO-HNS Vertigo Control Class A or B result (from daily diary count of number of attacks)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Patients with AAO-HNS Vertigo Control Class A or B</measure>
    <time_frame>6 months after treatment initiation</time_frame>
    <description>Percentage of patients in each group with an AAO-HNS Vertigo Control Class A or B result (from daily diary count of number of attacks)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in Dizziness Between Treatment Arms</measure>
    <time_frame>3 months after treatment initiation</time_frame>
    <description>Difference for each group in AAO-HNS dizziness functional disability scale from pre-treatment to 3 months after treatment initiation. A score improvement of 1 point on this 6-point scale will be considered significant improvement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects Experiencing Significant Hearing Fluctuation</measure>
    <time_frame>3 months after treatment initiation</time_frame>
    <description>Percentage of subjects in each treatment arm demonstrating clinically significant change in air conduction thresholds at &gt; 2 frequencies at 3 months (&gt; 10 dB change from baseline) or WDS (&gt; 15% change from baseline) compared to the worst audiogram and WDS in the 6 months prior to treatment initiation.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Meniere Disease</condition>
  <condition>Allergic Rhinitis</condition>
  <condition>Vertigo</condition>
  <arm_group>
    <arm_group_label>Montelukast 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be instructed to take one pill at night for 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be instructed to take one pill at night for 90 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast</intervention_name>
    <description>Each subject will be given a drug diary to record when they took the drug and any symptoms that they are experiencing, and will bring this diary and any unused pills to their next clinic visit before receiving the next 30-day supply. This process will continue for the full 90 days of study involvement, with a final visit 3 months later.</description>
    <arm_group_label>Montelukast 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Each subject will be given a drug diary to record when they took the drug and any symptoms that they are experiencing, and will bring this diary and any unused pills to their next clinic visit before receiving the next 30-day supply. This process will continue for the full 90 days of study involvement, with a final visit 3 months later.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults 18 years of age or older&#xD;
&#xD;
          -  Must meet all AAO-HNS 2020 criteria for definite Meniere's Disease&#xD;
&#xD;
          -  Must have a skin test positive for allergy&#xD;
&#xD;
          -  Is already a candidate for treatment with montelukast for allergic rhinitis/failed&#xD;
             first line over-the-counter allergy treatments&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Had a previous surgical procedure for treatment of vertigo&#xD;
&#xD;
          -  Currently receiving any allergy immunotherapy or taking montelukast or a beta-blocker&#xD;
&#xD;
          -  Pregnant or recent pregnancy ((â‰¤ 8 weeks postpartum), or lactation)&#xD;
&#xD;
          -  Current hospitalization for any reason&#xD;
&#xD;
          -  Any active, acute, or chronic pulmonary disorder other than asthma&#xD;
&#xD;
          -  History of intubation for asthma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary J Derebery, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>House Ear Clinic/House Institute Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mahta Marefat</last_name>
    <phone>(213) 770-1808</phone>
    <email>clinicaltrials@hifla.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>House Ear Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahta Marefat</last_name>
      <phone>213-770-1808</phone>
      <email>clinicaltrials@hifla.org</email>
    </contact>
    <investigator>
      <last_name>Mary J Derebery, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>House Institute Foundation</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahta Marefat</last_name>
      <phone>213-770-1808</phone>
      <email>clinicaltrials@hifla.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 19, 2021</study_first_submitted>
  <study_first_submitted_qc>March 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2021</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Hearing Loss</mesh_term>
    <mesh_term>Vertigo</mesh_term>
    <mesh_term>Meniere Disease</mesh_term>
    <mesh_term>Dizziness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

